Carlos Reyes-Sacin, MD
Infectious Disease · Montgomery, ALNPI 1902079577
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $70,330 of the $97,197 with a category attached, or 72.4%. Janssen Products, LP accounts for 98.1% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $40,341 and has fallen 99.5% since, to $222 in 2025. Among infectious disease clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 171 payments — averaging $568.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Janssen Products, LP$95K
- AbbVie$697
- Merck$352
- Johnson & Johnson$212
- Viiv Healthcare Company$207
- GSK$54
- plus $319 from 14 others
What the payments were for
- Consulting fees$3,0833%
- Speaking & faculty fees$70,33072%
- Travel & lodging$20,99122%
- Food & beverage$2,5673%
- Education$2260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Janssen Products, LP | 92 | $95,357 |
| AbbVie(2 entities) | 18 | $697 |
| Merck | 14 | $352 |
| Johnson & Johnson(2 entities) | 13 | $212 |
| Viiv Healthcare Company | 13 | $207 |
| GSK | 3 | $54 |
| Siemens Medical Solutions USA, Inc. | 2 | $51 |
| Theratechnologies Inc. | 2 | $35 |
| Abbott | 2 | $30 |
| Dexcom, Inc. | 2 | $28 |
| Cormedix Inc. | 1 | $28 |
| Shionogi Inc | 1 | $23 |
| Novo Nordisk | 1 | $21 |
| Lilly USA, LLC | 1 | $19 |
| Medtronic | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| Novartis | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $13 |
| Gilead | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$97,197 in reported general payments places this provider in the 95th percentile of 104 infectious disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 48 | $218,346 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 35 | $146,001 |
| TivicayDolutegravir Sodium | 29 | $64,546 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 14 | $48,907 |
| PrezcobixDarunavir/Cobicistat | 15 | $36,085 |
| DovatoDolutegravir Sodium/Lamivudine | 12 | $34,219 |
| Daptomycin | 17 | $33,152 |
| ErtapenemErtapenem Sodium | 31 | $13,916 |
| OzempicSemaglutide | 14 | $13,211 |
| Cefepime Hcl | 54 | $12,060 |
| Vancomycin Hcl | 81 | $9,876 |
| CeftriaxoneCeftriaxone Sodium | 48 | $6,592 |
| Ampicillin Sodium | 20 | $6,215 |
| Meropenem | 21 | $2,502 |
| Cefazolin Sodium | 30 | $2,445 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Janssen Products, LPSymtuza | $95,357 | $218,34648 claims |
| GileadBiktarvy | $11 | $146,00135 claims |
| Viiv Healthcare CompanyTivicay, Dovato | $207 | $98,76541 claims |
| Johnson & JohnsonPrezcobix | $212 | $36,08515 claims |
| Novo NordiskOzempic | $21 | $13,21114 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 104 infectious disease providers in Alabama.
Other infectious disease in Montgomery
- April TruettMontgomery$85K
- Glenn BedsoleMontgomery$1K
- Mladen SokanovicMontgomery$1K
- Ali HassounHuntsville$262K
- John BaddleyBirmingham$113K
- Christina MuznyBirmingham$111K
- Sonya HeathBirmingham$80K
- William GeislerBirmingham$63K
- Edward HookBirmingham$61K
- Edgar OvertonBirmingham$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.